Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 64, Issue 12, 1265-1273
Copyright © 2007 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lauster, C. D.
Right arrow Articles by Muench, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lauster, C. D.
Right arrow Articles by Muench, S. V.

Clinical Review

Vildagliptin: A novel oral therapy for type 2 diabetes mellitus

Colleen D. Lauster, Teresa P. McKaveney and Sarah V. Muench

COLLEEN D. LAUSTER, PHARM.D., CDE, is Assistant Professor, School of Pharmacy, University of Pittsburgh (UP), and Internal Medicine Pharmacist, UP Medical Center, Pittsburgh, PA. TERESA P. MCKAVENEY, B.S., is Research Assistant, School of Pharmacy, UP. SARAH V. MUENCH, PHARM.D., CDE, is Ambulatory Care Specialist, William Beaumont Hospital, Royal Oak, MI.

Address correspondence to Dr. Lauster at the Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, 302 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15261 (laustercd{at}upmc.edu).


Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.

Summary. Vildagliptin is an agent in a new class of medications called dipeptidyl peptidase IV (DPP4) inhibitors. By inhibiting DPP4, vildagliptin causes an increase in glucagon like peptide-1 (GLP-1), an intestinal hormone that aids in glucose homeostasis and insulin secretion. The manufacturer of vildagliptin received an approvable letter from the Food and Drug Administration in late February 2007. Vildagliptin has a halflife of about 90 minutes; however, ≥50% of DPP4 inhibition continues for more than 10 hours, allowing for once- or twice-daily dosing. Clinical trials have shown that vildagliptin is effective in significantly lowering glycosylated hemoglobin (HbA1c), fasting plasma glucose, and prandial glucose levels. Beta-cell function may also be improved. The most common adverse effects in patients receiving vildagliptin included headache, nasopharyngitis, cough, constipation, dizziness, and increased sweating. In most studies, the rate of hypoglycemia appeared to be similar to that of placebo.

Conclusion. In clinical trials of patients with type 2 diabetes mellitus, vildagliptin has been shown to reduce HbA1c, fasting plasma glucose levels, prandial glucose levels, and prandial glucagon secretion and to improve ß-cell function. If vildagliptin is approved for marketing, it will add to the available treatment options for diabetes and will provide patients and health care providers with another noninjectable therapy option.

Index terms: Antidiabetic agents; Diabetes mellitus; Dosage schedules; Drug interactions; Duration of action; Half-life; Mechanism of action; Pharmacokinetics; Toxicity; Vildagliptin

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Health-System Pharmacists.